-
Alpha Tau Medical Ltd. (DRTS) Misses Q1 EPS by 14c
-
Alpha Tau Medical Ltd. (DRTS) PT Raised to $15 at H.C. Wainwright
-
Alpha Tau reports interim brain cancer trial results in 3 patients
-
Alpha Tau to present head and neck cancer study at AHNS conference
-
Alpha Tau reports 100% disease control in pancreatic cancer trials
-
Alpha Tau Medical (DRTS) files $300M mixed shelf
-
Alpha Tau abstract accepted at ASCO annual meeting for pancreatic cancer data
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
Alpha Tau Medical Ltd. (DRTS) PT Raised to $9 at Citi
-
Alpha Tau Medical Ltd. (DRTS) Misses Q4 EPS by 30c
-
Piper Sandler Downgrades Alpha Tau Medical Ltd. (DRTS) to Neutral
-
Alpha Tau Medical Ltd. (DRTS) PT Raised to $12 at H.C. Wainwright
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
Sidoti Events, LLC's Year-End Virtual Investor Conference
-
Sidoti Events, LLC's Year-End Virtual Investor Conference
-
Sidoti Events, LLC's Year-End Virtual Investor Conference
-
Sidoti Events, LLC's Year-End Virtual Investor Conference
-
Alpha Tau Medical Ltd. (DRTS) Misses Q3 EPS by 27c
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
Alpha Tau Medical Ltd. (DRTS) Misses Q2 EPS by 11c
-
Alpha Tau Medical Ltd. (DRTS) Tops Q1 EPS by 2c
-
Alpha Tau Medical (DRTS) Appoints Nadav Kidron to its Board
-
Oramed Pharma (ORMP) Announces $36.9M Investment and Strategic Collaboration with Alpha Tau Medical
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
Piper Sandler Reiterates Overweight Rating on Alpha Tau Medical Ltd. (DRTS)
-
Alpha Tau Medical (DRTS) Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT for Patients with Recurrent Glioblastoma Multiforme
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)
-
Piper Sandler Reiterates Overweight Rating on Alpha Tau Medical Ltd. (DRTS)
-
Alpha Tau (DRTS) Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

